about
Metformin stimulates FGF21 expression in primary hepatocytes.GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors.Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.IFNγ and perforin cooperate to control infection and prevent fatal pathology during persistent gammaherpesvirus infection in mice.Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor.Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.Release of PYY from pig intestinal mucosa; luminal and neural regulation.Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination.Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae.Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis.Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs.MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver.Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.Meal-Stimulated Glucagon Release Is Associated with Postprandial Blood Glucose Level and Does Not Interfere with Glycemic Control in Children and Adolescents with New-Onset Type 1 DiabetesCo-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetesThe glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestineThe alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreasGLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestinePotential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected 125I-GLP-2Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the DayProglucagon processing in porcine and human pancreasEffect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy manGLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humansSecretion of neurotensin from isolated perfused porcine ileumTruncated glucagon-like peptide I, an insulin-releasing hormone from the distal gutLack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjectsTruncated glucagon-like peptide-1 (proglucagon 78-107 amide), an intestinal insulin-releasing peptide, has specific receptors on rat insulinoma cells (RIN 5AH)Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and miceColocalization of GLP-1 and GIP in human and porcine intestineA processing enzyme cleaving avian progastrin at post-Phe bondsParacrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in miceGlucometabolic consequences of acute and prolonged inhibition of fatty acid oxidationAfadin is a scaffold protein repressing insulin action via HDAC6 in adipose tissueInvestigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery
P50
Q29347106-183E36D2-98EF-46EC-9585-56F6B57CDA2EQ34367809-2BE844D1-E5DE-49A7-A830-6A0C032C3778Q35596753-EF3BFF93-8063-45A3-9876-5A6B48DF8834Q39030156-CF5F07B5-D56A-4E70-B19F-4C882F316011Q42227952-84B6759D-79EC-4718-8B27-19B1D6FBB6B3Q42266832-9CF47B60-7822-4597-860D-69E3C560780BQ42479294-019D4C67-F67F-4ED7-9655-6799A9341ABEQ42496399-EE093788-FD86-4398-964C-E6453A574365Q45378174-B755794A-BB3E-48B6-8513-035EA1F40CABQ46946154-4F3F1603-A107-418D-B6E9-5A073114E6B3Q47216488-38AE82AA-2E19-4393-AB50-CB10B68FA602Q47863805-3DDF477F-B054-4112-A063-74A87FDFE98DQ48528021-38348890-47B4-486B-B794-CE8992C18965Q50759032-6D7B6A4E-AAC7-41C5-8EE4-01FD69B75E73Q51578359-AF5D6E54-D991-4809-B9A2-ECDF39C95A94Q51581246-D7CF6696-C2DD-4603-B9DC-0A875B3B6D15Q51582586-A8959418-39EB-4817-8795-77E56A349676Q51630012-FBA69A8B-37C6-4792-9BB6-89F1E5CC304CQ52552570-D42FF1F7-5961-4581-9686-5ADF89D6ED44Q58224383-3CE02719-5185-4565-AE14-76E499624766Q58224395-58A03028-2697-4A57-A7FD-47ACC4C83FC1Q58447519-87858488-25A0-48C1-A2F0-7CA39C2CF8FFQ58448384-062513B3-FF33-44B7-A088-3FCF9AD5FA5FQ58448618-C50B07DA-A876-4157-B768-F26324758440Q58448762-87933214-4B7F-4D58-AC29-8AAB2F8B3CDCQ58449063-D6E1A382-3599-4B4D-8D69-57EDD260BACBQ58449151-7AF11889-0ABA-4194-9063-CA8C6E006DF3Q58449161-8B66DC05-6162-40D0-BDE1-3A5F05E20521Q58449333-6C6948B2-76A7-440F-9A6A-864332CEB515Q58449359-A5C44AF5-9101-4AA8-AB14-27EA4560343FQ58449388-57E6E369-0BFD-40CE-BF64-2F9A8478D900Q67599712-0124592F-F2CC-49FF-A1C8-B06FED78815AQ69820202-A74D7552-11FB-45BE-8DFC-1FD3F4CF10C8Q73218528-9D64AB95-1360-45CD-A2FD-192D9E748024Q73476547-C4F79740-1D17-4986-BA57-BBD78717461EQ73852600-8F12CAF1-1ADB-414D-AF38-B3661118D8D5Q90020443-EEDBA85F-4500-4B78-9228-0C276F982806Q91258949-C5432E2B-0608-4F06-8AC2-A05CFCB25C76Q91540868-728289B9-66A3-49E4-8617-D8B8AF905FE9Q91647199-DB37E67E-3E15-4E86-9EDD-0EB1E28347F9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cathrine Ørskov
@ast
Cathrine Ørskov
@en
Cathrine Ørskov
@es
Cathrine Ørskov
@nl
type
label
Cathrine Ørskov
@ast
Cathrine Ørskov
@en
Cathrine Ørskov
@es
Cathrine Ørskov
@nl
prefLabel
Cathrine Ørskov
@ast
Cathrine Ørskov
@en
Cathrine Ørskov
@es
Cathrine Ørskov
@nl
P106
P1153
7006319212
P31
P496
0000-0002-7762-2372